Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition

► Enhanced EGFR downregulation mediated by the XGFR bispecific antibodies. ► Novel bispecific format related effects upon ADCC induction. ► Potent induction of tumor growth inhibition in vivo.